PHARM Chapter 30 - Endocrine Pancreas and Glucose Homeostasis Flashcards
ME of
Acarbose
Miglitol
Voglibose
Alpha-Glucosidase Inhibitors - Carbohydrate analogues that bind avidly to intestinal brush border alpha-glucosidase enzymes - slowing breakdown and absorption of dietary carbohydrates (starch, dextrin, disaccharides)
Uses of
Acarbose
Miglitol
Voglibose
Type 2 diabetes mellitus
Continued use of alpha-glucosidase inhibitor associated with
diminishement of GI distress
Alpha-glucosidase inhibitors most useful for patients w
postrpandial hyperglycemia
new-onset patients w/ mild glycemia
Alpha-glucosidase ihibitors contraindicated in
Inflammatory bowel disease - delivery of undigested carbohydrates to distal bowel provides nutrients for colonic bacteria
ME of exogenous insulin
Classic anabolic hormone, promotes carbohydrate metabolism and facilitates glucose, amino acid, and triglyceride uptake and storage in liver, cardiac, and skeletal muscle, and adipose tissue
4 Prandial bolus exogenous insulins
Regular Insulin
Insulin lispro
Insulin aspart
Insulin glulisine
3 Basal “long-acting” exogenous insulins
NPH insulin
Insulin glargine
Insulin detemir
Uses of exogenous insulin
Diabetes mellitus
How are exogenous insulins delivered
parenternally, subcutanous is most commpon
Intermediate acting insulin that contains protamine which prolongs the time required for absorbtion
NPH insulin
Prandial bolus insulins
act rapidly, used to mimic B-cell release of insulin in response to nutreitn load
How is regular insulin stabilized for use and how long is it’s time of onset?
addition of zinc ions
30 minutes
NPH Insulin is formed how?
regular insulin suspended with zinc and protamine (arginine rich protien isolated from fish sperm) - peak activity occurs between 4-10 hours after administration, associated w/ increased hypoglycemia
Major SE of insulin therapy
in absence of carbs can result in hypoglycemia
What are the mainstay treatment for type 2 diabetics
sulfonylureas
4 first-generation sulfonylureas
acetohexamide
chlorpropamide
tolazamide
tolbutamide
5 second-generation sulfonylureas
glimepiride glipizide glibenclamide (glyburide) glicclazide gliquidone
ME of Sulfonylureas
inhibit B-cell K/ATP channel at SUR1 subunit - stimulates insulin release form pancreatic B cells and increase circulating insulin to lvels sufficient to overcome insulin resistance
Major adverse effect of SUlfonylureas
hypoglycemia from oversecretion of insulin
can cause weight gain secodnary to increased insulin activity in adipose tissue (better for nonobese)
Differences between first and second generation sulfonylureas in dosing
first generation bind w/ lower affinity to SUR1 so they must be administered at higher doses